🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 20 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 09/05/2003 | 12,11 | 12,27 | 12,00 | 12,13 | +0,00% | 2,23% | 424.300 |
| 08/05/2003 | 12,25 | 12,26 | 11,92 | 12,13 | -1,70% | 2,78% | 609.300 |
| 07/05/2003 | 13,20 | 13,20 | 12,25 | 12,34 | -5,80% | 7,20% | 643.700 |
| 06/05/2003 | 13,14 | 13,38 | 13,00 | 13,10 | +0,61% | 2,89% | 629.600 |
| 05/05/2003 | 12,77 | 13,19 | 12,48 | 13,02 | +2,12% | 5,56% | 775.000 |
| 02/05/2003 | 12,25 | 12,88 | 12,24 | 12,75 | +2,74% | 5,22% | 527.300 |
| 01/05/2003 | 12,02 | 12,57 | 11,52 | 12,41 | +2,90% | 8,74% | 633.900 |
| 30/04/2003 | 12,05 | 12,99 | 11,85 | 12,06 | +0,58% | 9,46% | 871.400 |
| 29/04/2003 | 11,50 | 12,35 | 11,50 | 11,99 | +0,76% | 7,39% | 486.800 |
| 28/04/2003 | 11,80 | 11,96 | 11,60 | 11,90 | +1,88% | 3,05% | 538.200 |
| 25/04/2003 | 11,59 | 11,99 | 11,07 | 11,68 | -0,17% | 7,94% | 853.600 |
| 24/04/2003 | 11,49 | 11,83 | 11,02 | 11,70 | +1,47% | 7,05% | 898.100 |
| 23/04/2003 | 11,07 | 11,61 | 10,85 | 11,53 | +4,44% | 6,87% | 643.200 |
| 22/04/2003 | 10,61 | 11,15 | 10,40 | 11,04 | +3,66% | 7,07% | 630.700 |
| 21/04/2003 | 10,37 | 10,75 | 10,37 | 10,65 | +1,43% | 3,66% | 634.400 |
| 17/04/2003 | 10,35 | 10,50 | 10,02 | 10,50 | +2,14% | 4,64% | 535.700 |
| 16/04/2003 | 10,32 | 10,55 | 10,13 | 10,28 | -1,06% | 4,07% | 445.400 |
| 15/04/2003 | 11,00 | 11,00 | 9,94 | 10,39 | -5,46% | 9,64% | 971.900 |
| 14/04/2003 | 10,67 | 11,11 | 10,49 | 10,99 | +3,39% | 5,81% | 320.900 |
| 11/04/2003 | 10,82 | 11,15 | 10,47 | 10,63 | -3,54% | 6,28% | 556.900 |
| 10/04/2003 | 11,03 | 11,16 | 10,68 | 11,02 | -0,45% | 4,35% | 552.300 |
| 09/04/2003 | 11,73 | 12,03 | 11,04 | 11,07 | -5,55% | 8,44% | 951.800 |
| 08/04/2003 | 12,08 | 12,25 | 11,68 | 11,72 | -3,30% | 4,72% | 1.196.600 |
| 07/04/2003 | 12,20 | 13,06 | 12,03 | 12,12 | +1,68% | 8,44% | 986.300 |
| 04/04/2003 | 12,06 | 12,27 | 11,63 | 11,92 | -2,61% | 5,31% | 651.700 |
| 03/04/2003 | 11,96 | 12,24 | 11,63 | 12,24 | +3,64% | 5,10% | 568.100 |
| 02/04/2003 | 11,23 | 12,17 | 11,09 | 11,81 | +7,36% | 9,62% | 1.589.300 |
| 01/04/2003 | 11,05 | 11,24 | 10,78 | 11,00 | -1,26% | 4,16% | 827.900 |
| 31/03/2003 | 11,04 | 11,38 | 11,02 | 11,14 | -3,30% | 3,26% | 686.000 |
| 28/03/2003 | 11,49 | 11,73 | 11,25 | 11,52 | +0,17% | 4,18% | 373.000 |